Hasil Pencarian  ::  Simpan CSV :: Kembali

Hasil Pencarian

Ditemukan 2 dokumen yang sesuai dengan query
cover
Astriviani Widyakusuma
"[ABSTRAK
Tujuan: Untuk mengevaluasi pengaruh pemberian suplementasi Mirtogenol terhadap perubahan ketebalan lapisan serabut saraf retina dan lapang pandang pada pasien dengan glaukoma primer sudut terbuka (GPSTa) dengan tekanan intraokular (TIO) terkontrol.
Metode: Penelitian ini merupakan penelitian prospektif, acak, tersamar ganda. Empat puluh satu pasien dengan GPSTa dengan TIO ≤ 18 mmHg diacak untuk mendapatkan Mirtogenol atau plasebo. Perubahan ketebalan RNFL dan MD lapang pandang diperiksa sebelum penelitian, 4 minggu serta 8 minggu setelah pemberian obat. Efek samping pengobatan ditanyakan kepada pasien selama penelitian.
Hasil: Rerata ketebalan RNFL kelompok Mirtogenol mengalami penurunan sebesar -0.70±1.63 μm dari 87.29±19.39 μm di awal penelitian menjadi 86.58±19.43 μm setelah 8 minggu, namun perubahan yang terjadi tidak bermakna secara statistik (p=0.121). Rerata ketebalan RNFL kelompok plasebo mengalami penurunan sebesar -1.74±1.79 μm dari 97.14±17.19 μm di awal penelitian
menjadi 95.40±18.56 μm setelah 8 minggu, perubahan yang terjadi bermakna secara statistik (p< 0.001). Rerata MD lapang pandang kelompok Mirtogenol mengalami peningkatan 0.542±1.93 dB setelah 8 minggu sedangkan rerata MD lapang pandang kelompok plasebo mengalami penurunan sebesar -0.083±1.36 dB setelah 8 minggu. Namun perubahan rerata MD lapang pandang kedua kelompok
tidak bermakna secara statistik (p>0.05). Selama penelitian tidak didapatkan adanya efek samping.
Kesimpulan: Mirtogenol dapat mempertahankan ketebalan lapisan serabut saraf retina, dan MD lapang pandang pada pemberian Mirtogenol cenderung meningkat.

ABSTRACT
Objective: To evaluate the effect of Mirtogenol towards the changes in retinal nerve fiber layer (RNFL) thickness and visual field in patients with primary open angle glaucoma (POAG) with controlled IOP.
Methods: This is a prospective, double blind, randomized study. Forty one POAG patients with IOP ≤ 18 mmHg were randomly assigned to receive either Mirtogenol or placebo. Changes in RNFL thickness and mean deviation of visual fields were evaluated before the treatment, as well as 4 weeks and 8 weeks after the treatment. Patients were asked for any side effects during the treatment period.
Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63 μm from 87.29±19.39 μm before the treatment to 86.58±19.43 μm after 8 weeks of treatment, however the change was not significant (p=0.121). The average RNFL thickness in the placebo group decreased -1.74±1.79 μm from 97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks of treatment, the change was statistically significant (p< 0.001). The average MD of visual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks of
treatment while the MD of visual field in the placebo group decreased 0.083 ± 1.36 dB after 8 weeks of treatment. Hoewever the changes in MD of visual field was not significant (p>0.05). No side effect was found throughout the study.
Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields.;Objective: To evaluate the effect of Mirtogenol towards the changes in retinal
nerve fiber layer (RNFL) thickness and visual field in patients with primary open
angle glaucoma (POAG) with controlled IOP.
Methods: This is a prospective, double blind, randomized study. Forty one
POAG patients with IOP ≤ 18 mmHg were randomly assigned to receive either
Mirtogenol or placebo. Changes in RNFL thickness and mean deviation of visual
fields were evaluated before the treatment, as well as 4 weeks and 8 weeks after
the treatment. Patients were asked for any side effects during the treatment period.
Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63
μm
from
87.29±19.39
μm
before
the
treatment
to
86.58±19.43
μm
after
8
weeks of treatment, however the change was not significant (p=0.121). The
average RNFL thickness in the placebo group decreased -1.74±1.79 μm from
97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks of
treatment, the change was statistically significant (p< 0.001). The average MD of
visual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks of
treatment while the MD of visual field in the placebo group decreased 0.083±1.36
dB
after
8
weeks
of
treatment.
Hoewever
the
changes
in
MD
of
visual
field
was
not
significant
(p>0.05).
No
side effect
was
found throughout
the
study.
Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields., Objective: To evaluate the effect of Mirtogenol towards the changes in retinal
nerve fiber layer (RNFL) thickness and visual field in patients with primary open
angle glaucoma (POAG) with controlled IOP.
Methods: This is a prospective, double blind, randomized study. Forty one
POAG patients with IOP ≤ 18 mmHg were randomly assigned to receive either
Mirtogenol or placebo. Changes in RNFL thickness and mean deviation of visual
fields were evaluated before the treatment, as well as 4 weeks and 8 weeks after
the treatment. Patients were asked for any side effects during the treatment period.
Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63
μm
from
87.29±19.39
μm
before
the
treatment
to
86.58±19.43
μm
after
8
weeks of treatment, however the change was not significant (p=0.121). The
average RNFL thickness in the placebo group decreased -1.74±1.79 μm from
97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks of
treatment, the change was statistically significant (p< 0.001). The average MD of
visual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks of
treatment while the MD of visual field in the placebo group decreased 0.083±1.36
dB
after
8
weeks
of
treatment.
Hoewever
the
changes
in
MD
of
visual
field
was
not
significant
(p>0.05).
No
side effect
was
found throughout
the
study.
Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields.]"
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2015
T58688
UI - Tesis Membership  Universitas Indonesia Library
cover
Dewinta Retno Kurniawardhani
"Perkembangan terapi adjuvan pada glaukoma untuk memperlambat progresi glaukoma saat ini terus dieksplorasi. Penelitian ini mengevaluasi efek Mirtogenol, pada perubahan perfusi okular (perfusi kapiler dan flux index), ketebalan lapisan serabut saraf retina (LSSR), dan tekanan intraokular (TIO) pada pasien glaukoma primer sudut terbuka (GPSTa) yang menerima terapi timolol maleat 0,5% tetes mata. Penelitian ini merupakan uji klinis acak terkontrol tersamar ganda. Terdapat 36 subjek (37 mata) dengan GPSTa dan TIO < 21 mmHg yang diacak untuk mendapatkan Mirtogenol atau plasebo selama 8 minggu. Kedua grup dibandingkan, pada kelompok Mirtogenol, rata-rata peningkatan perfusi kapiler dan flux index lebih baik, dan pada kuadran superior terdapat hasil yang signifikan secara statistik setelah 4 minggu (p=0.018). Rerata perbedaan ketebalan LSSR di seluruh kuadran terdapat penurunan dengan nilai yang lebih sedikit pada kelompok Mirtogenol (p>0.05). Penurunan TIO yang konsisten pada kelompok Mirtogenol setelah 8 minggu (p>0.05). Ditemukan efek samping pada 1 subjek yaitu gangguan lambung. Suplementasi Mirtogenol, sebagai terapi adjuvan pada pengobatan glaukoma dapat meningkatkan perfusi okular, mempertahankan ketebalan LSSR, dan menurunkan TIO.

The development of adjuvant therapies in glaucoma to slow its progression is currently being explored. This study evaluates the effects of Mirtogenol on changes in ocular perfusion (capillary perfusion and flux index), retinal nerve fiber layer (RNFL) thickness, and intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients receiving 0.5% timolol maleate eye drops. This study is a double-blind, randomized controlled clinical trial. There were 36 subjects (37 eyes) with POAG and IOP < 21 mmHg randomized to receive Mirtogenol or placebo for 8 weeks. Compared between the two groups, the Mirtogenol group showed a better average improvement in capillary perfusion and flux index, with statistically significant results in the superior quadrant after 4 weeks (p=0.018). The mean difference in RNFL thickness across all quadrants showed a smaller reduction in the Mirtogenol group (p>0.05). There was a consistent decrease in IOP in the Mirtogenol group after 8 weeks (p>0.05). One subject experienced side effects, specifically stomach disturbances. Mirtogenol supplementation, as an adjuvant therapy in glaucoma treatment, can improve ocular perfusion, maintain RNFL thickness, and reduce IOP."
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2024
SP-pdf
UI - Tugas Akhir  Universitas Indonesia Library